Pipeline
Techfields is dedicated to improving the clinical development of therapeutics. Our technology creates prodrugs from safe, clinically approved drugs to improve penetration into target tissues.
Our current clinical programs include X0002, indicated for pain related to osteoarthritis (knee and back), and TF0023, indicated for the hyperinflammatory state related to the complications from COVID-19 infection.
IND-enabling work has also been completed on a product indicated for depression. Several more products are in the early pipeline, including applications indicated for Parkinson’s disease, Alzheimer’s disease, antibiotic resistance, and sexual dysfunction.
| Product | Indications | Global Rights | Preclinical | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|---|
| X0002 |
|  | ||||
| TF0023 |
| | ||||
| TF0023 |
| | ||||
| TF0066 |
| | ||||
| TF0062 |
| | ||||
| TF0068 |
| | ||||
X0002
Global Rights- Pain from osteoarthritis (OA)
Preclinical Phase I Phase II Phase III
TF0023
Global Rights- Covid-19 (Therapeutic)
Preclinical Phase I Phase II Phase III
TF0023
Global Rights- Recovery of stroke and
heart attack - Pulmonary embolism
- Chronic heart failure
(CHF)
Preclinical Phase I Phase II Phase III
TF0066
Global Rights- Neuropathic pain
- Anti-depression
Preclinical Phase I Phase II Phase III
TF0062
Global Rights- Anti-obesity
Preclinical Phase I Phase II Phase III
TF0068
Global Rights- Parkinson
Preclinical Phase I Phase II Phase III
